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1. Introduction 
Neuroblastoma is the most frequent solid cancer of early childhood, its incidence is 10.2 
cases per million children under 15 years of age. Neuroblastoma is thought to be an 
embryonal tumor that is derived from precursor cells of the peripheral (sympathetic) 
nervous system (Hoehner et al., 1996; Maris, 2010). The tumor can arise anywhere along the 
sympathetic chain but is most frequently in the adrenal medulla and paraspinal ganglia 
(Maris, 2010). 
The most fascinating feature of neuroblastoma is its remarkable biological heterogeneity, 
which becomes apparent in the broad of the clinical courses of the disease. While some 
patients experience spontaneous regression or differentiation of the tumor into benign 
ganglioneuroma, others are affected by rapid and fatal tumor progression despite 
increasingly intensive strategies. This highly heterogeneous clinical behavior of disease 
makes the prediction of each patient’s individual risk at the time of diagnosis the major goal 
to choose the most adequate therapeutic approach.  
So far, the well-known tumor-specific genetic markers (amplification of the MYCN 
oncogene, DNA ploidy, chromosome 1p and 11q losses, and gains of chromosome 17q), 
patient age at diagnosis with two cut-offs of 12 and 18 months, the histopathological 
assessment (Shimada system), disease stage defined by the international neuroblastoma 
staging system (INSS) have been crucial determinants for the assignment of the risk class 
and the treatment plan. Currently, clinical trials stratify patients into four prognostic 
subgroups with expected very low risk, low risk, intermediate risk, and high risk of death 
from disease, and sixteen pretreatment designations (Cohn et al., 2009). 
However, according to the Surveillance, Epidemiology, and End Results databases 
(www.seer.cancer.gov), the survival rates, during the period from 1999 through 2005, have 
improved only for patients with the more benign form of the disease, the rates among 
children with high-risk neuroblastoma have shown only modest improvement, despite 
dramatic escalations in the intensity of therapy provided. The incorporation in clinical 
decision of additional genetic prognostic markers, including gene copy number aberrations, 
common genetic polymorphisms as well as gene expression and epigenetic markers is 
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believed to be crucial in the development of a more accurate classification of patients in 
distinct prognostic risk categories and so in making treatment decisions.  
The completion of the human genome sequence and the development of high throughput 
technology present exciting opportunities for the study of cancer. Recent technological 
advances based on whole genome approaches have made possible to discover a lot of new 
genetic markers in neuroblastoma which could be of substantial clinical importance in the 
relatively near future (Capasso and Diskin, 2010; Maris, 2010). Genome-wide analysis of 
amplification, deletion of genomic regions, somatically acquired genetic variations, common 
predisposing genetic variants, and mRNA expression profiles is a critical step to resolving 
the mechanisms of neuroblastoma tumorigenesis, might have implications towards better 
risk assessment and offer possibilities for target therapy. In this chapter, we will summarize 
the new discoveries related to the underlying molecular pathogenesis of this tumour with a 
special focus on advances that are translatable to the clinic. We will also present some 
recent, exciting findings from studies that have used a whole genome analysis technique 
such as comparative genomic hybridization (CGH), genome-wide association studies 
(GWAS), gene expression profiling (GEP) and next generation sequencing (NGS). We will 
finally discuss the clinical application of these whole genome searches and, the challenges 
and future directions for the genome-wide approaches to study the genetics of 
neuroblastoma. 
2. Comparative Genomic Hybridization (CGH) of neuroblastoma 
Genetic alternations such as amplifications and deletions frequently contribute to 
tumorigenesis. These alternations change the level of gene expression, which modify normal 
growth control and survival pathways. Characterization of these DNA copy-number 
changes is important for both the basic understanding of cancer and its diagnosis (Pinkel 
and Albertson, 2005). CGH was developed to survey DNA copy-number variations across a 
whole genome. With CGH, differentially labeled test (i.e. tumor) and reference (i.e. normal 
individual) genomic DNAs are cohybridized to normal metaphase chromosomes, and 
fluorescence ratios along the length of chromosomes provide a cytogenetic representation of 
the relative DNA copy-number variation. Chromosomal CGH resolution is limited to 10-20 
Mb – therefore, anything smaller than that will not be detected. In the few years, diverse 
studies have used in-house bacterial artificial chromosome array or cDNA microarray to 
identify novel cancer related genes or crucial genome copy number alterations that 
determine distinct genetic subgroups for risk stratification of neuroblastoma (Mosse et al., 
2005; Wang et al., 2006).  
In a most recent paper, investigating 165 primary neuroblastomas, Caren and colleagues 
have compared the survival of patient subgroups defined by genomic alterations (Caren et 
al., 2010). They have demonstrated that patients with only numerical chromosomal 
aberrations and no other alteration had a favorable long-term outcome. On the other hand, 
the survival of patients characterized by MYCN amplification, loss of 11q or gain of 17q was 
considerably worse, whereas no death or disease was observed in patients with tumors 
harboring segmental chromosome alterations other than those previously mentioned. The 
main significance of these results is that a small number of predictive genomic alterations is 
sufficient for risk assessment of neuroblastoma patients.  
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Another study conducted by Janoueix-Lerosey et al. examined almost 500 primary 
neuroblastomas by bacterial artificial chromosome array-CGH and indicated that global 
genomic profiles may add significant prognostic information to current neuroblastoma risk 
estimation (Janoueix-Lerosey et al., 2009). The analysis showed that two distinct genetic 
classes of neuroblastoma might be related to two different mechanisms of instability. One, 
characterized by whole chromosome changes without any segmental alteration, is 
associated with an excellent outcome even in patients older than 18 months or with 
advanced stages of disease. The other class presents segmental chromosome imbalances that 
mainly arise through unbalanced chromosome translocations leading to concomitant loss 
and gain of chromosome fragments. Patients included in this last class, regardless the 
MYCN amplification, have an increased risk of relapse and in general they show a worse 
prognosis. 
Another interesting CGH analysis has been performed on 236 primary neuroblastomas in 
Japan (Tomioka et al., 2008). The authors demonstrated that three major groups of genomic 
alterations in sporadic neuroblastomas could well define the prognoses of neuroblastomas:  
 GG-S (n=23): a genetic group of silent with no obvious losses and gains except MYCN 
amplification (5-year cumulative survival rate: 68%; DNA ploidy: 87% diploidy);  
 GG-P (n=53): a genetic group of partial chromosomal gains and ⁄ or losses (43% 
survival; 77% diploidy);  
 GG-W (n=36): a genetic group of whole chromosomal gains and ⁄ or losses (80% 
survival; 22% diploidy).  
In general, even if the results of these three excellent studies highlight the importance of 
prognostic classification of neuroblastoma using CGH, the clinical significance of global 
genomic alterations needs to be further evaluated in independent studies and compared 
with current risk estimation strategies.  
Currently, the clinical significance of this advanced technology is monitoring cancer 
progression and distinguishing between mild and metastatic censorious lesions using FISH 
(Florescence in situ hybridization) probes on regions of recurrent copy number aberrations 
in several tumor types. It can be also used to reveal more regional copy number markers 
that can be used for cancer prediction. Finally, identifying and understanding the genes that 
are involved in cancer will help to design therapeutic drugs that target the dysfunction 
genes and/or avoid therapies that cause tumor resistance. However, one of the limitations 
of CGH analysis is due to the contamination of stromal cells that can affect the copy number 
detection. The routine application of CGH in clinical practice might be considerably limited 
by the issue of contaminating stromal cells, because defined thresholds of tumor content 
will a priori exclude a substantial fraction of samples from the analysis.  
3. Gene Expression Profiling (GEP) of neuroblastoma 
Microarray-based gene expression profiling enables the rapid, simultaneous measurement 
of gene expression on a genome-wide scale and consequently this technology represents an 
exciting development in genomic marker research that has been enthusiastically embraced 
by researchers worldwide. 
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Comparison between neuroblastoma subsets with good and poor prognosis, or based on 
neuronal functions has indicated diverse gene expression markers such as the genes whose 
mRNA expression is high in the favorable type of neuroblastoma include TRKA, CD44, 
pleiotrophin, N-cadherin, H-RAS, ECEL1, NLRR3, BMCC1, NEDL1 and ZNF423, and those 
in the unfavorable ones include TRKB, TERT, CDC10, NLRR1, HEN2 and LMO3 (Ohira and 
Nakagawara, 2010). There are evidences in literature that indicate the tyrosine kinase 
receptors as tractable theraupetic targets due to their cell surface localization and limited 
normal tissue distribution (Maris, 2005). A phase I trial of lestaurtinib, a multi-kinase 
inhibitor that strongly inhibits TrkB, has recently been completed in children with refractory 
neuroblastoma (Minturn et al., 2011). This study has identified a well-tolerated oral dose 
that results in effective TrkB inhibition, and its efficacy will be studied in future pediatric 
clinical trials. However, none of the above mentioned candidate genes alone could 
sufficiently explain the different biological behavior of neuroblastoma tumors, or could be 
considered as a prognostic marker in a clinical setting.  
Global gene expression analysis can reveal significant information about the nature and 
state of cells, including disease progression, pharmacological response, and biological 
phenomena such as growth and development. These discoveries often point to sets of genes 
and gene pathways that are specifically associated with the state or change in state induced 
by disease. It also leads to the identification of gene sets associated with disease outcome 
and prognosis, as well as drug-induced responses. In many cases, only a small number of 
genes in the total genome (e.g., 25–500 genes) respond in a statistically significant way. The 
set can be further reduced by removing redundant genes. The resulting smaller subset 
becomes a true signature for diagnosis of the biological state and a predictor of therapeutic 
response. The identification of gene expression signatures is proving to be a powerful tool 
for disease diagnosis and drug discovery. For example, in oncology, microarray analysis is 
now being broadly applied toward the diagnosis and classification of a host of different 
cancers, including breast (van 't Veer et al., 2002), kidney (Vasselli et al., 2003), prostate (Best 
et al., 2003), and childhood cancers (Khan et al., 2001). Microarray analysis has also been 
used to categorize chemotherapy response and potentially direct the course of 
chemotherapy, for example, in acute myeloid leukemia (Okutsu et al., 2002).  
In the past few years, several reports have provided irrefutable, evidence that specific gene-
expression patterns can predict the natural courses of neuroblastoma patients with high 
accuracy. In the 2004, the first study showed a gene-expression-based classifier able to 
predict the prognosis of patients efficiently by profiling 56 tumors using cDNA microarrays 
containing 42 578 cDNA clones (classification accuracy was 95% for 21 test samples) (Wei et 
al., 2004). However, this study shows important limitations that prevented a diagnostic 
application of the proposed classifier: the low number of cases analyzed and the lack of 
validation analyses in independent sets of neuroblstomas. Since this first report on gene-
expression-based risk classification, there have been multiple attempts to define and 
validate an optimal mRNA prognostic expression signature in neuroblastoma.  
Ohira and colleagues, in the 2005, published a prognostic gene-expression signature for 
neuroblastoma patients that was derived from a large cohort of 136 primary neuroblastomas 
diagnosed in Japan (Ohira et al., 2005). They utilized an algorithm calculating survival 
probabilities of each patient at 2 years or 5 years after diagnosis, which is indicated by a 
“posterior” value range from 0 to 1. The gene expression signature was able to predict 
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patient prognosis with high efficiency (90% accuracy, 96% sensitivity and 90% specificity). 
Of note, an intermediate-risk group (stage 3 or 4 without MYCN amplification) was 
classified with an accuracy of 86% better than the current clinical markers (age, stage and 
MYCN) that exhibited 64% accuracy. The authors also made a “mini-chip” carrying the top-
ranked 200 genes for clinical use. It was tested on 50 independent tumor samples of all 
stages indicating high reproducibility as well as high efficiency. This ‘mini-chip’ is now 
under clinical validation in a larger cohort in Japan. 
In the 2006, Asgharzadeh et al. have built a classifier comprising 55 genes using 102 patients 
with metastatic, MYCN non-amplified neuroblastoma, that was able to separate patients 
into two groups with statistically different event-free survival rates (Asgharzadeh et al., 
2006). Regardless of MYCN status, all patients 18 months or older with metastatic 
neuroblastoma are currently considered high risk, and receive intensive therapies. The use 
of a molecular risk classification based on each tumor’s gene expression signature may be 
able to identify a subgroup with less aggressive disease that may not require intensive, high-
risk therapy. However, the 55-gene signature determined by Asgharzadeh et al. has not 
been validated in independent data sets, no trial for the this sub-group of patients is 
prospectively assessing the use of the 55-gene signature, so its clinical application is still far.  
Oberthuer et al., in the 2006, published a gene signature including 144-genes able to improve 
the risk estimation of current neuroblastoma trials (Oberthuer et al., 2006). They utilized a 
customized oligonucleotide microarray comprising 10,163 probes. The 144-gene signature 
obtained by analyzing 77 samples could classify 174 patients more accurately than risk 
stratification of current trials from Germany, Japan and the United States. To further 
evaluate the impact of this 144-gene expression-based classifier on the neuroblasotma risk 
classification, Oberthuer et al., in the 2010, determined its prognostic value in a validation 
cohort of 440 internationally collected neuroblastoma specimens, 125 of which were 
examined prospectively (Oberthuer et al., 2010). The results demonstrated that the 144-gene 
classifier improved the accuracy of discrimination of true low-risk patients who may need 
no chemotherapy at all from patient’s aggressive tumors who require intense cytotoxic 
treatment. The main limitation of these two studies is that a large number of genes has been 
included in the classifier and this might negatively influence its translation to the clinical 
routine as the costs to perform a gene expression analysis of 144 genes will be likely high. 
Even if the high number of genes analyzed can balance the outlying values of individual 
transcripts, and thus yield more stable classification results, the future directions for this 
kind of study will be construct small gene signatures with high accuracy and specificity of 
outcome prediction. This study strategy can more quickly facilitate the introduction of gene-
based classifiers into the clinical routine use. 
Another interesting gene signature was recently built (De Preter et al., 2010; Vermeulen et 
al., 2009). Based on an innovative data-mining strategy, the authors identified a 59-signature 
that was built using 30 training samples, tested on 313 test samples, and subsequently 
validated in a blind study on an independent set of 236 tumors. This gene signature can act 
as an independent risk predictor enabling the identification of patients with increased risk in 
the current European treatment group. This 59-gene classifier shows three important 
advantages compared to the previously published gene expression classifiers: the small 
amounts of starting material, the low number of genes, high cost-efficiency and speed of the 
quantification method (real-time quantitative polymerase chain reaction) and the possibility 
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of cross lab data comparison. This gene expression based classifier mostly responds to 
criteria for facing future studies to identify gene signatures that may be rapidly translated 
into the clinical management of neuroblastoma.  
In one study published in the 2010, (Fardin et al., 2010) and co-workers investigated the 
prognostic potential of hypoxia induced genes in neuroblastoma tumors. Hypoxia, a 
condition of low oxygen tension occurring in poorly vascularized areas, has profound 
effects on tumor cell growth, susceptibility to apoptosis, and resistance to radio- and 
chemotherapy. A biology-driven approach was chosen to define the hypoxia signature. The 
authors obtained a 62 probsets neuroblastoma hypoxia signature (NB-hypo) by performing 
a systematic analysis of the transcriptome of neuroblastoma cell lines cultured under 
hypoxic or normoxic conditions. NB-hypo signature efficiency were tested on 88 
neuroblastomas, it resulted be an independent prognostic factor for neuroblastoma. This 
study also supports the view that hypoxia is negatively correlated with tumors' outcome. 
However the performance of this signature has been assessed only in a modest set of 
patients and of course it needs to be tested in diverse and larger cohorts of neuroblastoma 
patients. 
3.1 Gene expression profiles of non-coding RNA  
MicroRNA (miRNA), a class of small non-coding RNA that regulates gene expression at a 
post-trascriptional level, has been studied in the context of cancer, and promising miRNA 
biomarkers have been identified for numerous major cancer types. miRNA are molecules 
comprising 22-25 nucleotide and function as negative regulators of gene expression. 
Literature data show that miRNAs can have a role in neuroblastoma and their expression 
correlates to prognosis, diagnosis and response to treatment. A recent whole genome search 
for MYCN target miRNA promoters differentially repressed under high MYCN conditions 
has indicated two miRs, miR-591 and miR-558, as potent tumor suppressors (Shohet et al., 
2011). An other interesting study, conducted by Lin and co-workers, has analyzed 66 
neuroblastoma tumors using a plausible neural networks to select a combination of 15 
biomarkers that consist of 12 miRNAs' signature, expression levels of Dicer and Drosha 
(miRNA processing enzymes that are required for the maturation of miRNAs), and age at 
diagnosis, were able to segregate all patients into four distinct patterns that were highly 
predictive of clinical outcome (Lin et al., 2010).  
4. Genome Wide Association Studies (GWAS) of neuroblastoma 
GWAS is indicated as an unbiased approach to revealing the risk alleles for genetically 
complex non-Mendelian disorders. One important characteristic of this advance technology 
is rapidly scanning markers across the complete sets of DNA, or genomes, of many people 
to find genetic variations associated with a particular disease. Indeed, during the past few 
years, this methodological approach has identified several affordable associations between 
specific chromosomal loci and common complex human disease. So far, GAWS have 
identified more than 200 new common low-penetrance susceptibility loci for cancers 
(NHGRI GWAS Catalog; http://www.genome.gov/gwastudies/). The discovery of new 
genetic associations is particularly useful in determining the genetic risk profile for a specific 
disease and so to develop better strategies to detect, treat and prevent the disease. 
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Moreover, GWAS analysis is very useful in identifying new disease genes and so to 
understand the functional consequences of these genes.  
Recently, by using a GWAS approach, we have identified multiple genetic risk factors 
associated with the neuroblastoma development and its clinical phenotypes (Table 1). Our 
data unequivocally demonstrate that multiple common DNA variations cooperate to 
increase the risk for neuroblastic malignant transformation. In the 2008, we identified the 
first predisposition locus by genotyping over 550,000 germline DNA SNPs from 1,752 
neuroblastoma pantients and 4.171 controls of European descent (Maris et al., 2008). Three 
common SNPs located in intronic region of the predicted genes LINC00340 (chromosome 
6p22) were strongly associated with the development of sporadic neuroblastoma. Of 
particular interest was the finding that not only were the three 6p22 SNPs associated with 
the likelihood of developing neuroblastoma, but patients who carried the 6p22 risk alleles 
were more likely to develop the clinically aggressive form of the disease and suffer tumor 
recurrence (Maris et al., 2008). We therefore performed a second genetic analysis, this time 
limiting the cases to those patients with high-risk neuroblastoma; we were able to identify a  
Table 1. Neuroblastoma susceptibility genes and variants identified by GWAS
Gene
Most 
Associated 
genetic variant
Type Location Risk allele
§
Estimated 
odds ratio
§
P-value Protein function References
FLJ22536 rs6939340 SNP 6p22 A 1.37
°Long intergenic non-
protein coding RNA 340
Maris et al., 
2008
BARD1 rs6435862 SNP 2q35 G 1.68 8.65X10
-18
Binding partner of
BRCA1; BRCA1–BARD1 
heterodimer has tumour-
suppressor functions; splice 
oncogenic functions
Capasso et al., 
2009
LMO1 rs110419 SNP 11p15 A 1.34 5.2x10
-16
Cysteine-rich transcriptional 
regulator with two LIM zinc-
binding domains
Wang et al., 
2011
DUSP12 rs1027702 SNP 1q23 T 2.01 3.38x10
-06
Member of the dual 
specificity protein 
phosphatase subfamily
Nguyen le et 
al., 2011
DDX4 rs2619046 SNP 5q11 T 1.48 5.70x10
-05
DEAD box proteins, 
characterized by the 
conserved motif Asp-Glu-
Ala-Asp (DEAD), are 
putative RNA helicases
Nguyen le et 
al., 2011
IL31RA rs10055201 SNP 5q11 A 1.49 3.85x10
-05
Type I cytokine receptor 
family
Nguyen le et 
al., 2011
HSD17B12 rs11037575 SNP 11p11 C 1.67 1.07x10
-06
Multifunctional isoenzyme 
functional in the conversion 
of estrone to estradiol (E2), 
and elongation of long-
chain fatty acids
Nguyen le et 
al., 2011
NBPF23
*rs11579261-     
rs3853524 CNV 1q21 - 2.49 2.97x10
-17
Novel member of the NBPF 
(neuroblastoma breakpoint 
family)
Diskin et al., 
2009
 
oOfficial full name provided by HUGO Gene Nomenclature Committee (HGNC) 
*Start point SNP and end point SNP of the CN 
§Odds Ratios and P-values as reported in the corresponding published research article 
Abbrevations: SNP, single nucleotide polymorphism; copy number variation 
Table 1. Neuroblastoma susceptibility genes and variants identified by GWAS 
LINC00340 
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new association with common intronic and nonsynonymous SNPs at the BARD1 tumor-
suppressor gene (Capasso et al., 2009). In this GAWS, we compared the allelic frequencies 
between more than 500 high-risk patients and 2043 controls, six SNPs at chromosome 2q35 
located within introns 1, 3 and 4 of BARD1 reached the genome-wide significant level. 
Furthermore, by TaqMan based genotyping in 540 high-risk neuroblastoma cases and 1,142 
controls, we demonstrated that also four nonsynonymous SNPs were genetic risk factors for 
the susceptibility to the development of high-risk neuroblastoma. BARD1 has been 
previously implicated in several cancers due to its association with BRCA1, a well-known 
breast cancer susceptibility gene. BARD1 heterodimerizes with BRCA1 and is thought to be 
necessary for the tumor suppressive function of BRCA1. Studies are ongoing to understand 
how sequence variations within BARD1 influence neuroblastoma tumorigenesis.  
Most recently, increasing of the number of cases and controls of the original GWAS cohort 
allowed us to identify a further predisposition locus at 11p15, within LIM domain only 1 
(LMO1) gene, a transcriptional regulator (using 1,627 neuroblastoma patients and 3,254 
controls) (Wang et al., 2011). Two SNPs were found to be associated with neuroblastoma in 
general and with high-risk neuroblastoma. Additional genomic analyses of DNA from 701 
primary neuroblastoma tumors demonstrated that a duplication of the LMO1, presents in 
12% of tumors, resulted in increased expression of LMO1 in cell lines and tumors and was 
associated with more advanced disease. Further functional experiments indicated LMO1 as 
an oncogene involved in the pathogenesis of neuroblastoma. 
To confirm the validity of these findings beyond the Caucasian population, an association 
test was performed by using the genotype data from 326 self-reported African-American 
neuroblastoma patients and 2500 African-American unaffected children. Devoto and co-
workers showed the first preliminary results at 60th annual meeting of The American Society 
of Human Genetics in November 2010. Among the known loci, the one that was most 
consistently replicated was BARD1, with six SNPs showing p-value less than 0.05 (smallest 
p-value equal to 0.0004 for rs7587476). Two SNPs in the LINC00340 region had nominally 
significant p-value, and only one in LMO1. Overall these results support the hypothesis that 
the same genetic factors affect risk of neuroblastoma in both populations. 
An other published article that utilized a GWAS approach to detect allelic risk variants 
suggested again that neuroblastoma is both phenotypically and genetically heterogeneous. 
Indeed, an analysis restricted to low-risk neuroblastoma cases identified predisposing loci 
for less aggressive disease within four additional genes: DUSP12 at 1q23.3, DDX4 and 
IL21RA both at 5q11.2 and HSD17B12 at 11p11.2 (Nguyen le et al., 2011). Interestingly, the 
same risk alleles resulted to be not associated with high-risk neuroblastoma. Furthermore, a 
single SNP replication analysis in an Italian cohort of 115 low-risk cases and 680 controls 
showed that the three most significant SNPs (rs1027702, rs2619046, rs11037575) in the three 
loci that contain DUSP12, DDX4/IL31RA, and HSD17B12, respectively were confirmed to be 
genetic risk factors for the susceptibility to the development of low-risk neuroblastoma. 
Together, these results suggest that genetic initiating events may predispose not only to 
neuroblastoma, but to clinically relevant sub-phenotypes as well.  
We are currently adding new cases and controls to our data sets for both United States 
population and Italian population. Moreover, we are utilizing alternative strategies for 
finding those genetic risk loci hidden among signals discarded by multiple testing 
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corrections needed in the analysis of GWAS data. Toghether these two approaches will 
allow us to identify new genetic variants associated with neuroblastoma. 
The next few years will see the completion and publication of additional genome-wide scans 
that involve higher resolution tools and substantially larger DNA collections than have been 
used before. Even when performed with exquisite resolution, however, association and 
epidemiology studies are limited in their power to prove causation. Thus, effective 
functional studies will be required that connect genetic variation with disease 
pathophysiology. Furthermore, while GWAS are a valuable tool for assessment of the effects 
of common polymorphisms, the aggregate role of low-frequency rare functional gene 
variants in neuroblastoma has not been properly evaluated. Uncommon variants with 
relatively large effects might account for part of the unexplained heritability in 
neuroblastoma. Moreover, some of these rare variants might reside in genes previously 
identified in GWAS. Rare genetic variation is not well represented in current databases or 
commercially available fixed arrays, and can be only ascertained by targeted deep 
sequencing of samples from affected individuals (Nejentsev et al., 2009). 
4.1 Copy Number Variations (CNVs) based GWAS  
In addition to SNP genotypes, CNVs (deletion or duplication of segments of germline DNA) 
represent a significant source of genetic diversity that may influence disease susceptibility. 
An analysis of copy number at 550,000 SNPs in germiline DNA from 1,441 neuroblastoma 
cases and 4,160 controls identified a common deletion polymorphism spanning less than 
145-Kb at 1q21.1 associated with neuroblastoma, no duplications reached genome-wide 
significance (Diskin et al., 2009). A novel member of the NBPF (“neuroblastoma breakpoint 
family”) gene family mapping within the CNV was cloned and sequenced. Expression of 
this transcript, termed NBPF23, was found to be significantly correlated with the underlying 
CNV genotype in neuroblastoma tumors and cell lines, further supporting the biological 
relevance of the CNV association (Diskin et al., 2009). The highest levels of NBPF23 
expression were seen in fetal brain and sympathetic ganglia and expression was directly 
correlated with CNV status in neuroblastoma cells, implicating NBPF23 in the molecular 
pathogenesis of neuroblastoma. Further CNVs-based GWAS analyses are ongoing and it is 
likely that other CNVs affect the neuroblstoma development.  
The results from GWAS are clearly telling us that common, heritable genetic variants 
contribute to the predisposition for sporadic neuroblastoma (Figure 1). We now can state 
that the neuroblastoma belongs to the group of complex genetic diseases, which are 
common disorders characterized by modest disease-risk heritability and multifaceted 
interactions between genetic and environmental factors. The full list of disease genes 
(susceptibility and modifiers) and environmental triggers in neuroblastoma remains 
incomplete (Figure 1). Moreover these studies are giving an important contribution in 
understanding the complex genetic architecture of neuroblastoma and in providing valuable 
insight into the underlying tumor biology. Identifying the genes and pathways involved in 
predisposing individuals to neuroblastoma may also lead us to the development of novel 
treatments. On the other hand, we can not state that there is an immediate clinical utility of 
knowing an individual genotype at these disease variants. However it is plausible to 
prefigure that the discovery of many others single disease risk variants, disease risk gene-
gene and gene-environment interactions toghether with the development of new statistical 
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methods (able to construct reliable disease predictor) will make feasible the clinical 
application of these GWAS findings in the relatively near future. Indeed, predictive 
modeling might be substantially created if more-penetrant variants are identified, and 
transcriptional signatures and accurate environmental exposures are taken into account. 
The translational potential of such modeling might extend to redefining disease 
classification, prognosticating progression, and predicting treatment responses and/or 
adverse effects. 
 
 
 
Fig. 1. Genetic model of neuroblastoma. Four scenarios in which gene-gene and gene-
environmental interactions play a crucial role might characterize the model of genetic 
susceptibility to neuroblastoma. (A) Both genetic and environmental components do not 
exceed so that there is not malignant transformation in patients without ALK or PHOX2B 
mutations. (B) There is an excess of the environmental component, which induces the 
malignant transformation in patients without ALK or PHOX2B mutations. (C) Multiple 
common DNA variations (excess of the genetic component) in a large number of genes can 
cooperate to reach the threshold malignant transformation in patients without ALK or 
PHOX2B mutations. (D) A mutation in the ALK or PHOX2B gene results in a single, highly 
penetrant risk allele that interacting with environmental factors allows a malignant 
transformation. 
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5. Genome-wide linkage analysis of familial neuroblastoma  
An other important genome-wide approach, utilizing high density SNP-based microarray 
technology, made possible the identification of three separate missense mutations within 
coding exons of the anaplastic lymphoma kinase (ALK) gene which were responsible for 
familial neuroblastoma (Mosse et al., 2008). While almost 99% of neuroblastoma occurs 
sporadically the remaining 1-2% of neuroblastoma has a familial history (Maris, 2010). 
This genome-wide approach was utilized in an attempt to identify linkage signals that 
might identify predisposition loci for the majority of hereditary neuroblastoma pedigrees, 
which do not harbor germline PHOX2B mutations (explaining only a small subset of 
cases). Six thousands SNPs were genotyped in 176 individuals from 20 families with 
hereditary neuroblastoma. ALK gene which maps to 2p23 is a receptor protein-tyrosine 
kinase which functions as an oncogene in many human cancers, most notably through 
translocations resulting in constitutive activation of the ALK kinase domain as seen in 
anaplastic large cell lymphomas (Morris et al., 1994), inflammatory myofibroblastic 
tumors (Griffin et al., 1999), squamous cell carcinomas (Jazii et al., 2006), and non-small 
cell lung cancers (Soda et al., 2007). The ALK and PHOX2B mutations are responsible for 
approximately 90% of hereditary neuroblastoma. Based on these data a genetic testing 
could be created for facilitating the identification of unaffected siblings who carry highly 
penetrant germline mutations and would justify screening in an attempt to ensure early 
detection of neuroblastoma. By using an exome high-throughput sequencing, researchers 
are now attempting to find the heritable genetic etiology in the remaining rare families 
with evidence of hereditary neuroblastoma that do not harbor ALK or PHOX2B germline 
mutations.  
Of note, somatic ALK mutations or amplifications were also identified in 6-9% of sporadic 
cases (Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008). According to the 
recent success of small molecule tyrosine kinase inhibitors in a certain subset of cancers, 
such as gefitinib in non-small-cell lung carcinoma with epidermal growth factor receptor 
(EGFR) mutations, a similar therapeutic approach based on inhibition of ALK-mediated 
signaling will be expected to target oncogenic ALK mutations in neuroblastoma (Li and 
Morris, 2008).  
In a recent study a novel activating mutation in ALK (F1174) in a neuroblastoma patient in 
the course of analysis of genomic DNA from patient biopsy samples has been identified 
(Martinsson et al., 2011). The appearance of this novel F1174S ALK mutant correlated with 
the development of aggressive disease at the patient level with emergence of therapy 
resistance and fatal outcome. This study points out an important issue regarding the 
possibility of the occurrence of genomic mutation events during the disease outcome. So, the 
initial screening in the first tumor biopsy of a patient is not sufficient and further molecular 
analyses of the ALK locus, in particular in tumor progression and/or tumor relapse, is 
warranted for better understanding of the treatment of neuroblastoma patients. 
6. Next Generation Sequencing (NGS) of neuroblastoma 
Over the past four years, there has been a fundamental shift away from the application of 
automated Sanger sequencing for genome analysis. The automated Sanger method is now 
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considered as a ‘first-generation’ technology, and newer methods are referred to as next 
generation sequencing. This sequencing method that has emerged since 2005 parallelizes 
the sequencing process and produces millions of typically short sequence reads (50–400 
bases) from amplified DNA clones. In general, the field of cancer genomics has been 
impacted most profoundly by the application of next generation sequencing technology, 
which has tremendously accelerated the pace of discovery while dramatically reducing 
the cost of data production. Hence, there has been a rapid progression from targeted gene 
re-sequencing using PCR and Sanger sequencing to either targeted, whole genome, or 
whole transcriptome sequencing using these massively parallel sequencing platforms, 
coupled with the requisite bioinformatics-based approaches to analyze the data. There are 
particular challenges for the detection and diagnosis of cancer genome alterations. For 
example, some genomic alterations in cancer are prevalent at a low frequency in clinical 
samples, often owing to substantial admixture with non-malignant cells. Second-
generation sequencing can solve such problems (Thomas et al., 2006). Furthermore, these 
new sequencing methods make it feasible to discover novel chromosomal rearrangements 
(Campbell et al., 2008) and microbial infections (MacConaill and Meyerson, 2008) and to 
resolve copy number alterations at very high resolution (Campbell et al., 2008; Chiang et 
al., 2009).  
So far, only a few studies have utilized this advanced methodology to search genetic 
alterations responsible of the neuroblastoma initiation. To identify potential drug targets 
against recurrent neuroblastoma, Morozova and colleagues used next generation RNA 
sequencing and/or human exon arrays to profile the transcriptomes of 11 tumor-initiating 
cells from six neuroblastoma patients, revealing genes that are highly expressed in the 
tumor-initiating cells compared with normal neural crest-like cells and unrelated cancer 
tissues (Morozova et al., 2010). This analysis revealed 30 targets with an available inhibitor, 
six of which have never been implicated in neuroblastoma. Further validation analyses were 
performed on one of the six novel drug targets, AURKB. Interestingly, a selective AURKB 
inhibitor, AZD1152, was cytotoxic to neuroblastoma tumor-initiating cells used in the study 
but not to normal pediatric neural crest-like precursor cells. This is the first report of 
AURKB inhibitors as potential therapeutics for neuroblastoma. However, AURKB inhibitors 
are currently in clinical trials so it is reasonable to forecast a rapid translation of this 
observation to neuroblastoma therapy. 
Another recently published study shows that miRNA-based classifiers can be used to 
stratify neuroblastoma patients according to clinical course (Schulte et al., 2010). The small 
RNA transcriptomes of five favorable and five unfavorable neuroblastomas were 
analyzed using SOLiD next-generation sequencing, generating a total of more than 
188,000,000 reads. Favorable and unfavorable neuroblastomas were distinguishable by 
hierarchical clustering of miRNA patterns. Expression of single miRNAs also differed 
significantly between the two groups. The authors then identified 13 candidates for novel 
miRNAs of which three were further validated in 70 primary neuroblastomas using RT-
qPCR. 
However, in literature, there is no published research article showing the use of next 
generation sequencing to search for somatically acquired DNA mutations in sporadic 
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neuroblastoma. The most significant impact of next generation sequencing on cancer 
genomics has been the ability to re-sequence, analyze and compare the matched tumor and 
normal genomes of a single patient. Many studies have identified several mutations 
responsible of the development of diverse cancers (Bass et al., 2011; Puente et al.; Wei et 
al., 2011). About neuroblastoma, a large collaborative effort, the Therapeutically 
Applicable Research to Generate Effective Treatments (TARGET) project 
(http://target.cancer.gov), is leveraging genomic profiling techniques to help identify the 
molecular mechanisms that drive oncogenesis and to discover new therapeutic targets. 
The first results have been shown at 102nd Annual Meeting of American Association for 
Cancer Research in April 2011. So far, the exome sequencing of 81 tumor/normal pairs 
from high-risk neuroblasotma patients has been completed. Pugh and colleagues reported 
that several genes resulted significantly mutated including ALK (6 tumors) and PTPN11 
(3 tumors). Interestingly, there were 27 other genes with candidate mutation frequencies 
in the 4-10% range, but no single gene was identified with a mutation frequency greater 
than 10%. Morozova and co-authors instead presented a study about a whole genome 
shotgun sequencing of six stage 4 MYCN-non-amplified and four stage 4 MYCN-
amplified neuroblastomas cases and matched peripheral blood, as well as whole 
transcriptome sequencing of the corresponding tumor RNA. The analysis of tumor and 
normal genomes revealed an average of 1664 candidate somatic mutations per case, the 
majority of which were single nucleotide variants and small indels falling within introns 
or intergenic sequence. Moreover, an average of 10% of candidate somatic mutations in 
coding sequence was expressed in the transcriptome representing candidate oncogenic 
events. Of note, two novel somatic gene fusions, between TRIM37 on chromosome 17 and 
RNF121 on chromosome 11, and between LSAMP and STAG1 on chromosome 3, 
previously uncharacterized in neuroblastoma, were identified. 
It is likely that the biggest impact of second-generation sequencing of cancer genomes will 
be in cancer diagnostics. The major challenge will be to make biological sense of the 
mountains of genomic data. This will require computational, biological and clinical analyses 
of the genome data. These developments might potentiate accurate genome-based diagnosis 
for patients with neuroblastoma. Moreover, this advanced technology will rapidly identify 
therapeutic targets that will have implications in developing new and effective treatments 
for this devastating disease. 
7. Whole genome searches to open the door to the personalized medicine 
Recent advances in genomics are likely to change the molecular characterization of cancer 
and provide a path for the personalized treatment of patients with cancer. The generation of 
comprehensive catalogs of genetic alterations could inform strategies for effective 
prevention and early detection, as well as guiding the development of therapeutics in the 
appropriate patient subpopulation. Genome searches also hold great potential to inform the 
prognosis and guide evidence-based management of early stage diseases, which comprise 
an increasing proportion of cancer diagnoses. It is likely that whole genome searches will 
drive the transition from a morphology-based to a genetics-based taxonomy of cancer, point 
of care decisions will become increasingly customized to the unique genomic and proteomic 
features of a patient’s tumor. These molecular changes might be evaluated in circulating 
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tumor cells or in tumor biopsies or in body fluids (plasma, lymph and ascites) using specific 
diagnostic tests that can predict the probability of clinical benefit for all treatment options.  
Genome searches have provided an important contribution in the risk stratification of 
neuroblastoma. To date, the International Neuroblastoma Risk Group (INRG) Task Force 
has assessed several potential prognostic factors in 8800 patients. These factors included 
stage, age, lactate dehydrogenase, as well as certain genetic markers such as MYCN 
amplification, chromosome 1p, 17q, and 11q aberration, and ploidy. After appropriate 
statistical analyses, four risk groups were established and the current consensus scheme 
includes stage, age, histologic category, grade of tumor differentiation, MYCN status, 11q 
aberration, and tumor cell ploidy as final criteria (Cohn et al., 2009). According to the INRG 
Task Force, these four risk groups were designed to stratify children into more homogenous 
pretreatment groups. Despite these efforts, more needs to be done to decrease the death 
rates of children with neurobalstoma and the upcoming whole genome searches might play 
a main role in both improving risk stratification and developing more appropriate 
treatments. Indeed, genome-wide analyses have already identified diverse therapeutic 
targets and biological agents are currently tested. They include small molecule inhibitors of 
genetic pathways implicated in tumor growth, such as inhibitor of the phosphoinositide 3-
kinase/mammalian target of rapamycin pathway; insulin-like growth factor 1 receptor; 
ALK; Aurora kinase A and B; tyrosine receptor kinase, and histone deacetylase inhibitors. It 
is plausible that by the inclusion of biological end points in large cooperative studies, further 
insight will be gained about the underlying pathways in the tumorigenesis of 
neuroblastoma, which will lead to new therapies to improve outcome. 
8. Future directions 
Since the publication of the Human Genome Project data, medical practice and research 
have entered the genome era. From a predominant focus on single genes and disease-related 
mutations has emerged the technology to assay the genome in its entirety and the first 
means to interpret findings in a comprehensive manner. Several genome-wide approaches 
have been used to study neuroblastoma and several information about molecular 
mechanisms underlying the neuroblastic malignant transformation, and genomic or genetic 
abnormalities associated with neuroblastoma and its clinical phenotypes have been 
obtained. This allows us to understand how to ameliorate therapeutic treatments of 
neuroblstoma and how to optimize risk group classification. However, despite extensive 
research, relatively few genomic markers have been implemented into routine clinical use 
and the survival rate for neuroblastoma high-risk patients is still low ( 40%). Integrative 
genomic approaches incorporating data from high-throughput genomic technologies are 
needed, on the one hand, to facilitate our understanding of neuroblastoma pathogenesis and 
consequently to accelerate the development of more effective therapies, on the other hand, 
to improve risk estimation of children with neuroblastoma (Figure 2). To give strong push 
for the achievement of these two objectives, inter and intra-disciplinary collaborations of 
biologists, chemists, clinicians, computer scientists, and mathematicians are strongly 
warranted. Furthermore, sharing and availability on public depositories of scientific results 
from neuroblastoma whole genome studies and in general from cancer studies are very 
important start points to get the main aim of research work: increasing the percentage of 
children who beat this devastating disease.  
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Fig. 2. Integrated genome-wide approaches in neuroblastoma. The integration of diverse 
genome-wide-based analyses will provide a large amount of biological and genetic 
information that presumably will determinate the identification of individual predisposition 
to the clinical sub-groups of neuroblastoma, the refinement of risk stratification and 
development of new and effective cures. Overall the integrated application of these 
approaches will lead us to improve the survival of children with high-risk neuroblastoma. 
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